	US 12,419,862 B2
	Use of a cathepsin s inhibitor against the formation of anti-drug antibodies
Christian Klein, Schlieren (CH); Fabrice Alain Andre Kolb, Basel (CH); Marianne Manchester Young, Basel (CH); Syed Sohail Ahmed, Basel (CH); and Juliana Mattos De Almeida Bessa, Basel (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Mar. 18, 2021, as Appl. No. 17/206,044.
Application 17/206,044 is a continuation of application No. PCT/EP2019/074918, filed on Sep. 18, 2019.
Claims priority of application No. 18195251 (EP), filed on Sep. 18, 2018.
Prior Publication US 2021/0315863 A1, Oct. 14, 2021
Int. Cl. A61K 31/4155 (2006.01); A61P 37/06 (2006.01); C07K 16/24 (2006.01)

CPC A61K 31/4155 (2013.01) [A61P 37/06 (2018.01); C07K 16/241 (2013.01)]

23 Claims

1. A method for reducing or preventing the formation of anti-drug antibodies (ADA) against a biologic in a subject receiving a treatment with said biologic comprising administering a cathepsin S inhibitor to said subject, wherein the cathepsin S inhibitor is administered to the subject in an amount that is sufficient to reduce or prevent the formation of ADA against the biologic in said subject, wherein the cathepsin S inhibitor is (2S,4R)-4-[4-(1-methyl-1H-pyrazol-4-yl)-2-trifluoromethyl-benzenesulfonyl]-1-(1-trifluromethyl-cyclopropanecarbonyl)-pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide; or

(2S, 4R)-4-[4-(5-methyl-tetrazol-2-yl)-2-trifluoromethyl-benzenesulfonyl]-1-(1-trifluromethyl-cyclopropanecarbonyl)-pyrrolidine-2-carboxyilic acid (1-cyano-cyclopropyl)-amide;

or a pharmaceutically acceptable salt thereof.